CN101260401A - 编码一种癌症新标记的基因 - Google Patents

编码一种癌症新标记的基因 Download PDF

Info

Publication number
CN101260401A
CN101260401A CNA2008100031485A CN200810003148A CN101260401A CN 101260401 A CN101260401 A CN 101260401A CN A2008100031485 A CNA2008100031485 A CN A2008100031485A CN 200810003148 A CN200810003148 A CN 200810003148A CN 101260401 A CN101260401 A CN 101260401A
Authority
CN
China
Prior art keywords
lab
glu
sequence
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008100031485A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯A·拉多舍维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmvaRx Inc
Original Assignee
ImmvaRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImmvaRx Inc filed Critical ImmvaRx Inc
Publication of CN101260401A publication Critical patent/CN101260401A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2008100031485A 1998-03-17 1999-03-11 编码一种癌症新标记的基因 Pending CN101260401A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040485 1998-03-17
US09/040,485 US6166176A (en) 1998-03-17 1998-03-17 Cancer marker protein and peptides thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB998061697A Division CN100372938C (zh) 1998-03-17 1999-03-11 编码一种癌症标记的基因

Publications (1)

Publication Number Publication Date
CN101260401A true CN101260401A (zh) 2008-09-10

Family

ID=21911225

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008100031485A Pending CN101260401A (zh) 1998-03-17 1999-03-11 编码一种癌症新标记的基因
CNB998061697A Expired - Fee Related CN100372938C (zh) 1998-03-17 1999-03-11 编码一种癌症标记的基因

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB998061697A Expired - Fee Related CN100372938C (zh) 1998-03-17 1999-03-11 编码一种癌症标记的基因

Country Status (14)

Country Link
US (7) US6166176A (enExample)
EP (1) EP1062346B1 (enExample)
JP (2) JP2002512005A (enExample)
CN (2) CN101260401A (enExample)
AP (1) AP2000001917A0 (enExample)
AT (1) ATE337400T1 (enExample)
AU (2) AU762758B2 (enExample)
BR (1) BR9908886A (enExample)
CA (1) CA2323494A1 (enExample)
DE (1) DE69932926T2 (enExample)
EA (1) EA003735B1 (enExample)
IL (1) IL138208A0 (enExample)
OA (1) OA11487A (enExample)
WO (1) WO1999047683A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
JP2006502110A (ja) * 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
DK1512695T3 (da) * 2003-09-04 2009-03-16 Biomay Ag Hypoallergeniske polypeptider på fiske-parvalbumin
US7413737B2 (en) * 2003-11-14 2008-08-19 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
RU2340896C1 (ru) * 2007-05-17 2008-12-10 Негосударственное научно-исследовательское учреждение "Биомедицинский центр" Способ диагностики онкологических заболеваний
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
WO2020123964A1 (en) * 2018-12-13 2020-06-18 Labyrx Immunologic Therapeutics (Usa) Limited Labyrinthin-based peptides for cancer immunotherapies and uses thereof
CN113993892A (zh) * 2019-01-08 2022-01-28 莱比锡免疫治疗(美国)有限公司 靶向迷路蛋白或其部分的构建体以及所述构建体的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816402A (en) * 1986-01-07 1989-03-28 Northwestern University Murine hybridoma and diagnostic antibody produced thereby
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5728819A (en) * 1996-08-02 1998-03-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5994062A (en) 1995-10-02 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Epithelial protein and DNA thereof for use in early cancer detection
US6166176A (en) 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6344548B1 (en) * 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US7135617B2 (en) * 1998-07-02 2006-11-14 Calgene Llc Diacylglycerol acyl transferase proteins
US6100077A (en) * 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US7045326B2 (en) * 2001-02-23 2006-05-16 The Regents Of The University Of California Mono- and diacylglycerol acyltransferases and methods of use thereof
US20030161831A1 (en) * 2001-02-23 2003-08-28 Sylvaine Cases Mono-and diacylglycerol acyltransferases and methods of use thereof
CA2492205A1 (en) * 2002-07-31 2004-02-05 Monsanto Technology, Llc Diacylglycerol acyltransferase nucleic acid sequences and associated products
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
US8507754B2 (en) * 2009-01-31 2013-08-13 University Of North Texas Engineering lipids in vegetative tissues of plants
CA2804025C (en) * 2010-06-28 2023-02-21 Commonwealth Scientific And Industrial Research Organisation Methods of producing lipids

Also Published As

Publication number Publication date
BR9908886A (pt) 2000-11-21
US20100233711A1 (en) 2010-09-16
HK1033151A1 (en) 2001-08-17
US7329743B2 (en) 2008-02-12
EP1062346A1 (en) 2000-12-27
AU762758B2 (en) 2003-07-03
EA200000845A1 (ru) 2001-08-27
US6166176A (en) 2000-12-26
CA2323494A1 (en) 1999-09-23
US8163883B2 (en) 2012-04-24
JP2002512005A (ja) 2002-04-23
US20100112582A1 (en) 2010-05-06
US20110110963A1 (en) 2011-05-12
AU2003204331B2 (en) 2008-02-07
US6727080B1 (en) 2004-04-27
IL138208A0 (en) 2001-10-31
AU2999699A (en) 1999-10-11
DE69932926T2 (de) 2007-05-24
OA11487A (en) 2004-05-04
EA003735B1 (ru) 2003-08-28
US7635759B2 (en) 2009-12-22
ATE337400T1 (de) 2006-09-15
US20080249284A1 (en) 2008-10-09
CN100372938C (zh) 2008-03-05
AP2000001917A0 (en) 2000-09-30
WO1999047683A1 (en) 1999-09-23
CN1301302A (zh) 2001-06-27
US20050208508A1 (en) 2005-09-22
DE69932926D1 (de) 2006-10-05
EP1062346B1 (en) 2006-08-23
JP2009165492A (ja) 2009-07-30
WO1999047683A9 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
US7635759B2 (en) Gene encoding labyrinthin, a marker for cancer
KR100380503B1 (ko) 흑색종관련항원성폴리펩티드,그에피토프및흑색종에대한백신
CA1252046A (en) Methods for oncogenic detection
Rydlander et al. Molecular characterization of a tissue‐polypeptide‐specific‐antigen epitope and its relationship to human cytokeratin 18
HK1039749A1 (en) Use of expressions of ctl and t-helper lymph cells in vaccination
AU2001286896A1 (en) A recombinant monoclonal antibody to phosphotyrosine-containing proteins
CA2192678A1 (en) Mn gene and protein
JPH11514859A (ja) 肝腫瘍性疾患に関連する遺伝子
JP4190291B2 (ja) 癌細胞の増殖を調節するのに有用なポリヌクレオチド
WO1996029402A1 (en) Tumor marker protein for cancer risk assessment
JP4041913B2 (ja) 抗腫瘍タンパク質およびその遺伝子
US6297361B1 (en) Use of histidine decarboxylase immunoreactivity to detect human cancer
HK1122838A (en) A gene encoding for a novel marker for cancer
MXPA00008836A (en) Gene encoding labyrinthin, a marker for cancer
JP2003525059A (ja) 新規ヒトｕｌｉｐ／ｃｒｍｐタンパク質と癌及び傍新形成性神経症候群の診断及び治療におけるその使用
NZ507014A (en) A gene encoding a novel marker for cancer
HK1033151B (en) Gene encoding labyrinthin, a marker for cancer
JPH11222499A (ja) プロテアソーム抑制蛋白質およびそれをコードするポリヌクレオチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122838

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080910

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1122838

Country of ref document: HK